The next generation of skin rejuvenation
NEOSTRATA®, a pioneer in dermatological skincare innovation, proudly introduces MicroDiPeptide²²⁹®, a cutting-edge peptide technology designed to visibly lift, firm, and sculpt the skin. The result of over eight years of molecule development, this breakthrough reinforces NEOSTRATA’s legacy of innovation in skincare science. MicroDiPeptide²²⁹® now enhances the renowned Skin Active range, delivering next-level skin rejuvenation backed by clinical research.
Breakthrough peptide science: 2.5 times smaller for superior penetration
Unlike conventional skincare peptides, MicroDiPeptide²²⁹® is a proprietary, patented dipeptide, setting a new benchmark in skin penetration and efficacy. Engineered to be 2.5 times smaller than traditional cosmetic peptides, it meets the 500 Dalton Rule, ensuring deep absorption into the skin’s surface for maximum impact. This advanced technology directly targets the skin’s natural support matrix, addressing multiple signs of ageing for a firmer, more youthful appearance.
Clinically proven to strengthen skin’s natural support matrix
MicroDiPeptide²²⁹® works by stimulating five key biological pathways that contribute to firmness, elasticity, and hydration:
- Pro-collagen – enhances skin structure and firmness
- Elastin – improves elasticity and resilience
- Hyaluronic acid – boosts moisture retention for plump, hydrated skin
- Decorin – regulates collagen assembly for improved skin tightness
- Fibronectin – strengthens the extracellular matrix for a smoother, more even complexion
Dermatologist-recommended for sensitive and eczema-prone skin
Backed by rigorous clinical testing, MicroDiPeptide²²⁹® has demonstrated remarkable anti-ageing benefits and is suitable for even sensitive and eczema-prone skin. Studies in patients with eczema revealed a significant reduction in visible lesions, highlighting its anti-inflammatory properties. Unlike traditional anti-ageing ingredients like retinol, MicroDiPeptide²²⁹® is gentle yet highly effective, making it an ideal choice for those seeking visible results without irritation.
“As a company, we are committed to bringing innovative and science-backed solutions to our customers. The ground-breaking MicroDiPeptide²²⁹®, which was the last active project that founders Dr Eugene J Van Scott, a dermatologist, and Dr Ruey J Yu, OMD, PhD, a dermopharmacologist, worked on, represents a significant advancement in skincare. This patented technology, with its unique micro-sized molecules, helps improve the delivery of active ingredients, lifting and firming the skin, reducing puffiness, and enhancing overall skin texture. It continues the founders’ legacy of pioneering work in skin health, and we are proud to carry forward their mission and offer products that truly make a difference.” – Lorna Bowes, CEO of AestheticSource
FURTHER INFORMATION
AestheticSource
www.aestheticsource.com
